|
1
|
Burke M, Pabbidi MR, Farley J and Roman
RJ: Molecular mechanisms of renal blood flow autoregulation. Curr
Vasc Pharmacol. 12:845–858. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Touyz RM: Molecular and cellular
mechanisms in vascular injury in hypertension: Role of angiotensin
II. Curr Opin Nephrol Hypertens. 14:125–131. 2005.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Nogueira A, Piresi MJ and Oliveira PA:
Pathophysiological mechanisms of renal fibrosis: A review of animal
models and therapeutic strategies. In vivo. 31:1–22.
2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Hewitson TD: Renal tubulointerstitial
fibrosis: Common but never simple. Am J Physiol Renal Physiol.
296:F1239–F1244. 2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
López-Novoa JM, Martínez-Salgado C,
Rodríguez-Peña AB and López-Hernández FJ: Common pathophysiological
mechanisms of chronic kidney disease: Therapeutic perspectives.
Pharmacol Ther. 128:61–81. 2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Tanase DM, Gosav EM, Costea CF, Ciocoiu M,
Lacatusu CM, Maranduca MA, Ouatu A and Floria M: The intricate
relationship between type 2 diabetes mellitus (T2DM), insulin
resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J
Diabetes Res. 2020(3920196)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Remuzzi G, Benigni A and Remuzzi A:
Mechanisms of progression and regression of renal lesions of
chronic nephropathies and diabetes. J Clin Invest. 116:288–296.
2006.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Owens EP, Vesey DA, Kassianos AJ, Healy H,
Hoy WE and Gobe GC: Biomarkers and the role of mast cells as
facilitators of inflammation and fibrosis in chronic kidney
disease. Transl Androl Urol. 8 (Suppl 2):S175–S183. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Fan J, Xie K, Wang L, Zheng N and Yu X:
Roles of inflammasomes in inflammatory kidney diseases. Mediators
Inflamm. 2019(2923072)2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Meng XM, Nikolic-Paterson DJ and Lan HY:
Inflammatory processes in renal fibrosis. Nat Rev Nephrol.
10:493–503. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Fogo AB: Progression and potential
regression of glomerulosclerosis. Kidney Int. 59:804–819.
2001.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gupta J, Mitra N, Kanetsky PA, Devaney J,
Wing MR, Reilly M, Shah VO, Balakrishnan VS, Guzman NJ, Girndt M,
et al: Association between albuminuria, kidney function, and
inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc
Nephrol. 7:1938–1946. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wynn TA and Ramalingam TR: Mechanisms of
fibrosis: Therapeutic translation for fibrotic disease. Nat Med.
18:1028–1040. 2012.PubMed/NCBI View
Article : Google Scholar
|
|
14
|
Sievers LK and Eckardt K: Molecular
mechanisms of kidney injury and repair in arterial hypertension.
Int J Mol Sci. 20(2138)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gabriele MM and Nogueira PCK: Management
of hypertension in CAKUT: Protective factor for CKD. Front Pediatr.
7(222)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Liang S, Le W, Liang D, Chen H, Xu F, Chen
H, Liu Z and Zeng C: Clinico-pathological characteristics and
outcomes of patients with biopsy-proven hypertensive
nephrosclerosis: A retrospective cohort study. BMC Nephrol.
17(42)2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Maranduca MA, Tarniceriu CC, Carasevici E
and Cojocaru E: Interaction between angiotensin II, hypertension
and inflammation in rat kidney. Rev Med Soc Nat. 119:791–797.
2015.
|
|
18
|
Mărănducă MA, Cojocaru E and Carasevici E:
Correlations between arterial hypertension induced by angiotensin
II and systemic inflammation in rat. Rev Med Chir Soc Med Nat Iasi.
120:77–82. 2016.PubMed/NCBI
|
|
19
|
Hill GS: Hypertensive nephrosclerosis.
Curr Opin Nephrol Hypertens. 17:266–270. 2008.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Jordan J: Device-based approaches for the
treatment of arterial hypertension. Curr Hypertens Rep.
19(59)2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
VanDeVoorde RG and Mitsnefes MM:
Hypertension and CKD. Adv Chronic Kidney Dis. 18:355–361.
2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Schaefer B and Wühl E: Educational paper:
Progression in chronic kidney disease and prevention strategies.
Eur J Pediatr. 171:1579–1588. 2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Klahr S and Morrissey JJ: The role of
vasoactive compounds, growth factors and cytokines in the
progression of renal disease. Kidney Int Suppl. 57:S7–S14.
2000.PubMed/NCBI
|
|
24
|
Liang XB, Ma LJ, Naito T, Wang Y, Madaio
M, Zent R, Pozzi A and Fogo AB: Angiotensin type 1 receptor blocker
restores podocyte potential to promote glomerular endothelial cell
growth. J Am Soc Nephrol. 17:1886–1895. 2006.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Liebau MC, Lang D, Böhm J, Endlich N, Bek
MJ, Witherden I, Mathieson PW, Saleem MA, Pavenstädt H and Fischer
KG: Functional expression of the renin-angiotensin system in human
podocytes. Am J Physiol Renal Physiol. 290:F710–F719.
2006.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kobori H, Ozawa Y, Suzaki Y,
Prieto-Carrasquero MC, Nishiyama A, Shoji T, Cohen EP and Navar LG:
Young Scholars Award Lecture: Intratubular angiotensinogen in
hypertension and kidney diseases. Am J Hypertens. 19:541–550.
2006.PubMed/NCBI View Article : Google Scholar
|
|
27
|
el Nahas AM, Muchaneta-Kubara EC, Essawy M
and Soylemezoglu O: Renal fibrosis: Insights into pathogenesis and
treatment. Int J Biochem Cell Biol. 29:55–62. 1997.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Rodríguez-Peña A, Prieto M, Duwel A, Rivas
JV, Eleno N, Pérez-Barriocanal F, Arévalo M, Smith JD, Vary CP,
Bernabeu C and López-Novoa JM: Up-regulation of endoglin, a
TGF-beta-binding protein, in rats with experimental renal fibrosis
induced by renal mass reduction. Nephrol Dial Transplant. 16 (Suppl
1):S34–S39. 2001.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Cattran DC and Rao P: Long-term outcome in
children and adults with classic focal segmental
glomerulosclerosis. Am J Kidney Dis. 32:72–79. 1998.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Pei Y, Cattran D, Delmore T, Katz A, Lang
A and Rance P: Evidence suggesting under-treatment in adults with
idiopathic focal segmental glomerulosclerosis. Regional
glomerulonephritis registry study. Am J Med. 82:938–944.
1987.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Maranduca MA, Tanase DM, Branisteanu DC,
Serban DN, Branisteanu DE and Serban IL: Involvement of
proinflammatory cytokines in angiotensin II-induced hypertension in
rat. Exp Ther Med. 20:3541–3545. 2020.PubMed/NCBI View Article : Google Scholar
|
